Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers
Technical Report,01 Aug 2013,31 Jul 2016
Massachusetts General Hospital Boston United States
Pagination or Media Count:
This project has made very good progress. We have now unveiled an even larger role for defective apoptosis in the emergence of resistance. We have been very successful in our ability to generate cell lines derived from patient biopsies both before treatment and at the time of resistance. We are now using these patient-derived cell lines to assess BIM levels and apoptotic response to next-generation inhibitors.